A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Recruiting

Phase 1

Phase 2

A2B395A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Sponsor:

A2 Biotherapeutics Inc.

Code:

NCT06682793

Conditions

Solid Tumor, Adult

Colorectal Cancer

Non-Small Cell Lung

NSCLC (Non-small Cell Lung Cancer)

Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

A2B395

xT CDx with HLA-LOH assay

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-18. This information was provided to ClinicalTrials.gov by A2 Biotherapeutics Inc. on 2025-09-09.